Vir Biotechnology said its Phase 3 ECLIPSE 1 trial in chronic Hepatitis Delta met the primary endpoint. The late-stage result marks a key milestone for elebsira

Vir Biotechnology said its Phase 3 ECLIPSE 1 trial in chronic Hepatitis Delta met the primary endpoint. The late-stage result marks a key milestone for elebsiran and tobevibart in a high-unmet-need liver disease; more details are due on a conference call.